| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Antonio Cerasa, Giacomo Koch, Giulia Donzuso, Graziella Mangone, Maurizio Morelli, Livia Brusa, Mario Stampanoni Bassi, Viviana Ponzo, Silvia Picazio, Luca Passamonti, Maria Salsone, Antonio Augimeri, Carlo Caltagirone, Aldo Quattron. A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias. Brain : a journal of neurology. vol 138. issue Pt 2. 2015-03-23. PMID:25414038. |
levodopa-induced dyskinesias are disabling motor complications of long-term dopamine replacement in patients with parkinson's disease. |
2015-03-23 |
2023-08-13 |
Not clear |
| Fanny Charbonnier-Beaupel, Marion Malerbi, Cristina Alcacer, Khadija Tahiri, Wassila Carpentier, Chuansong Wang, Matthew During, Desheng Xu, Paul F Worley, Jean-Antoine Girault, Denis Hervé, Jean-Christophe Corvo. Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 35. issue 1. 2015-03-20. PMID:25568106. |
in parkinson's disease, long-term dopamine replacement therapy is complicated by the appearance of l-dopa-induced dyskinesia (lid). |
2015-03-20 |
2023-08-13 |
mouse |
| Tanya Chotibut, Victoria Fields, Michael F Salvator. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals. Molecular pharmacology. vol 86. issue 6. 2015-02-12. PMID:25208966. |
norepinephrine transporter inhibition with desipramine exacerbates l-dopa-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals. |
2015-02-12 |
2023-08-13 |
rat |
| Yong Wang, Qiao Jun Zhang, Hui Sheng Wang, Tao Wang, Jian Li. Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia. Synapse (New York, N.Y.). vol 68. issue 8. 2015-02-02. PMID:24599755. |
unfortunately, chronic administration of this dopamine precursor causes l-dopa-induced dyskinesia (lid), which is a debilitating complication whose pathogenesis remains unclear. |
2015-02-02 |
2023-08-12 |
human |
| Philippe Huot, Tom H Johnston, Katie D Lewis, James B Koprich, M Gabriela Reyes, Susan H Fox, Matthew J Piggott, Jonathan M Brotchi. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. vol 82. 2015-01-09. PMID:24447715. |
uwa-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-dopa anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the mptp-lesioned common marmoset. |
2015-01-09 |
2023-08-12 |
marmoset |
| Emma Thornton, Mark Macquarie Hassall, Frances Corrigan, Robert Vin. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model. Parkinsonism & related disorders. vol 20. issue 5. 2015-01-07. PMID:24637127. |
dyskinesia or abnormal involuntary movements (aims) are a disabling effect of chronic l-dopa administration and consequent pulsatile stimulation of dopamine receptors. |
2015-01-07 |
2023-08-12 |
Not clear |
| Qing Ye, Xiao-Lei Yuan, Jie Zhou, Can-Xing Yuan, Xu-Ming Yan. Effect of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias. Evidence-based complementary and alternative medicine : eCAM. vol 2014. 2014-12-05. PMID:25477990. |
effect of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias. |
2014-12-05 |
2023-08-13 |
rat |
| Qing Ye, Xiao-Lei Yuan, Jie Zhou, Can-Xing Yuan, Xu-Ming Yan. Effect of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias. Evidence-based complementary and alternative medicine : eCAM. vol 2014. 2014-12-05. PMID:25477990. |
this study was performed to observe the effects of zishenpingchan granule on neurobehavioral manifestations and the activity and gene expression of striatal dopamine d1 and d2 receptors of rats with levodopa-induced dyskinesias (lid). |
2014-12-05 |
2023-08-13 |
rat |
| Nicolas Morin, Vincent A Jourdain, Marc Morissette, Laurent Grégoire, Thérèse Di Paol. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Neuropharmacology. vol 79. 2014-12-03. PMID:24456747. |
brain glutamate overactivity is well documented in parkinson's disease (pd) and antiglutamatergic drugs decrease l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesias (lid); the implication of dopamine neurotransmission is not documented in this anti-lid activity. |
2014-12-03 |
2023-08-12 |
monkey |
| Tatsuya Ueno, Junko Yamada, Haruo Nishijima, Akira Arai, Keisuke Migita, Masayuki Baba, Shinya Ueno, Masahiko Tomiyam. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia. Neurobiology of disease. vol 64. 2014-11-12. PMID:24398173. |
levodopa-induced dyskinesia (lid) is a major complication of long-term dopamine replacement therapy for parkinson's disease, and becomes increasingly problematic in the advanced stage of the disease. |
2014-11-12 |
2023-08-12 |
rat |
| M Chondrogiorgi, A Tatsioni, H Reichmann, S Konitsioti. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. European journal of neurology. vol 21. issue 3. 2014-09-29. PMID:24313869. |
dopamine agonist monotherapy in parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials. |
2014-09-29 |
2023-08-12 |
Not clear |
| Rolf Heumann, Rosario Moratalla, Maria Trinidad Herrero, Koushik Chakrabarty, René Drucker-Colín, Jose Ruben Garcia-Montes, Nicola Simola, Micaela Morell. Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. Journal of neurochemistry. vol 130. issue 4. 2014-09-29. PMID:24773031. |
dopamine replacement therapy in parkinson's disease is associated with several unwanted effects, of which dyskinesia is the most disabling. |
2014-09-29 |
2023-08-13 |
Not clear |
| N Nevalainen, S Af Bjerkén, G A Gerhardt, I Strömber. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. Neuroscience. vol 260. 2014-09-25. PMID:24361918. |
serotonergic nerve fibers in l-dopa-derived dopamine release and dyskinesia. |
2014-09-25 |
2023-08-12 |
rat |
| N Nevalainen, S Af Bjerkén, G A Gerhardt, I Strömber. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. Neuroscience. vol 260. 2014-09-25. PMID:24361918. |
nevertheless, knowledge of l-dopa-induced events that could lead to development of dyskinesias are limited and therefore the present work has evaluated (i) the role of the 5-ht system in l-dopa-derived dopamine synthesis when dopamine neurons are present, (ii) l-dopa-induced effects on striatal dopamine release and clearance, and on 5-ht nerve fiber density, and (iii) the behavioral outcome of altered 5-ht transmission in dyskinetic rats. |
2014-09-25 |
2023-08-12 |
rat |
| Paulo Bugalho, Albino J Oliveira-Mai. Impulse control disorders in Parkinson's disease: crossroads between neurology, psychiatry and neuroscience. Behavioural neurology. vol 27. issue 4. 2014-09-07. PMID:23242359. |
in this review, we discuss some unresolved issues regarding pd-icds, including the association with psychiatric co-morbidities such as obsessive-compulsive disorder and with dopamine related side effects, such as hallucinations and dyskinesias; the relationship with executive cognitive dysfunction; and the neural underpinnings of icds in pd. |
2014-09-07 |
2023-08-12 |
Not clear |
| Matthieu F Bastide, Sandra Dovero, Giselle Charron, Gregory Porras, Christian E Gross, Pierre-Olivier Fernagut, Erwan Bézar. Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia. Neurobiology of disease. vol 62. 2014-09-03. PMID:24103779. |
long-term l-3,4-dihydroxyphenylalanine (l-dopa) treatment in parkinson's disease (pd) leads to l-dopa-induced dyskinesia (lid), a condition thought to primarily involve the dopamine d1 receptor-expressing striatal medium spiny neurons. |
2014-09-03 |
2023-08-12 |
rat |
| Eunju Shin, Carlo Lisci, Elisabetta Tronci, Camino Fidalgo, Roberto Stancampiano, Anders Björklund, Manolo Cart. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation. Neurobiology of disease. vol 62. 2014-09-03. PMID:24135006. |
graft-induced dyskinesia (gid) is a serious complication induced by dopamine (da) cell transplantation in parkinsonian patients. |
2014-09-03 |
2023-08-12 |
rat |
| Na Wu, Xinxin Yang, Lu Song, Jianglei Wei, Zhenguo Li. Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease. Drug design, development and therapy. vol 7. 2014-08-29. PMID:24376341. |
recent studies have shown that expression of g protein-coupled receptor kinase 6 (grk6) and β-arrestin1 in the striatum is closely associated with hyperactive dopamine receptors in rats with levodopa-induced dyskinesia (lid). |
2014-08-29 |
2023-08-12 |
rat |
| Elaine Del-Bel, Fernando Eduardo Padovan-Neto, Raphael Escorsim Szawka, Célia Aparecida da-Silva, Rita Raisman-Vozari, Janete Anselmo-Franci, Angélica Caroline Romano-Dutra, Francisco Silveira Guimarae. Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment. Neurotoxicity research. vol 25. issue 1. 2014-08-28. PMID:23807548. |
l-dopa-induced dyskinesia was mitigated by 7-nitroindazole, which also decreased dopamine turnover, dopamine and dopac levels. |
2014-08-28 |
2023-08-12 |
rat |
| Chiara Fiorentini, Paola Savoia, Daria Savoldi, Cristina Missal. Receptor heteromers in Parkinson's disease and L-DOPA-induced dyskinesia. CNS & neurological disorders drug targets. vol 12. issue 8. 2014-08-28. PMID:24040823. |
here, we provide an overview of the functional implications of physical interactions among dopamine, glutamate and adenosine receptors, their relevance for striatal msns activity and their involvement in the physiopathology of pd and dyskinesia. |
2014-08-28 |
2023-08-12 |
Not clear |